TCF.L

TheraCryf plc
Theracryf PLC - Issue of Equity and Total Voting Rights
14th November 2024, 15:24
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 3178M
Theracryf PLC
14 November 2024
 

A black background with blue letters Description automatically generated

 

TheraCryf plc

("TheraCryf", the "Company" or the "Group")

Issue of Equity and Total Voting Rights

Alderley Park, UK - 14 Nov 2024: TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on oncology and neuropsychiatry, announces that the Company has issued 2,275,527 new ordinary shares of 0.25 pence each in the capital of the Company ("Ordinary Shares") in lieu of professional fees.

Application will be made for 2,275,527 Ordinary Shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur on or around 20 November 2024 and the Ordinary Shares will, on issue, rank pari passu in all respects with the Company's existing Ordinary Shares.

On Admission, the Company will have a total of 429,622,422 Ordinary Shares in issue. No Ordinary Shares are held in treasury. The figure of 429,622,422 may be used by the Company's shareholders as the denominator in the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure, Guidance and Transparency Rules.

 

-Ends-

Enquiries

TheraCryf plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO

+44 (0)1625 315 090
enquiries@theracryf.com

Cavendish Capital Markets (NOMAD and Broker)
 Geoff Nash / Teddy Whiley / Rory Sale (Corporate Finance)
Nigel Birks / Harriet Ward (ECM)

+44 20 7220 0500

Vigo Consulting
 Rozi Morris

+44 207 7390 0230
theracryf@vigoconsulting.com

 

About TheraCryf

TheraCryf is a clinical stage drug development company focussing on oncology and neuropsychiatry. The Company has a broad clinical and preclinical pipeline in indications including glioblastoma*, neurodevelopmental disorders, addiction, anxiety and narcolepsy* [*orphan indications].

Its strategy is to generate compelling data sets to preclinical and/or clinical proof of concept and partner its clinical programmes with mid-size to large pharma for larger trials and commercialisation, including Stalicla SA, in neurodevelopmental disorders. The Company has sourced know how for programmes from companies such as Shire (now Takeda).

TheraCryf has worked with and has ongoing collaborations with major universities and hospitals such as the University of Manchester, La Sapienza (Università di Roma), the Erasmus Medical Centre, Rotterdam, Kings College London and the University of Michigan.

The Company has its headquarters and registered office at Alderley Park, Cheshire. It is listed on AIM in London and trades under the ticker symbol TCF. 

For further information, please visit: www.theracryf.com 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEQKQBBPBDDBDD]]>
TwitterFacebookLinkedIn